vs

Side-by-side financial comparison of Astrana Health, Inc. (ASTH) and PJT Partners Inc. (PJT). Click either name above to swap in a different company.

Astrana Health, Inc. is the larger business by last-quarter revenue ($950.5M vs $531.4M, roughly 1.8× PJT Partners Inc.). PJT Partners Inc. runs the higher net margin — 10.0% vs 0.7%, a 9.4% gap on every dollar of revenue. On growth, Astrana Health, Inc. posted the faster year-over-year revenue change (42.9% vs 12.9%). PJT Partners Inc. produced more free cash flow last quarter ($138.6M vs $-6.0M). Over the past eight quarters, Astrana Health, Inc.'s revenue compounded faster (53.3% CAGR vs 27.5%).

Astrana Health, Inc. is a U.S.-based value-based healthcare services provider that primarily serves Medicare-eligible senior populations across the United States. It offers in-home primary care, chronic disease management, and care coordination services, aiming to improve patient health outcomes and reduce unnecessary medical costs.

PJT Partners, Inc. is a global advisory-focused investment bank, founded in October 2015 as part of The Blackstone Group's spin-off of its financial and strategic advisory services businesses.

ASTH vs PJT — Head-to-Head

Bigger by revenue
ASTH
ASTH
1.8× larger
ASTH
$950.5M
$531.4M
PJT
Growing faster (revenue YoY)
ASTH
ASTH
+30.0% gap
ASTH
42.9%
12.9%
PJT
Higher net margin
PJT
PJT
9.4% more per $
PJT
10.0%
0.7%
ASTH
More free cash flow
PJT
PJT
$144.5M more FCF
PJT
$138.6M
$-6.0M
ASTH
Faster 2-yr revenue CAGR
ASTH
ASTH
Annualised
ASTH
53.3%
27.5%
PJT

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
ASTH
ASTH
PJT
PJT
Revenue
$950.5M
$531.4M
Net Profit
$6.6M
$53.4M
Gross Margin
Operating Margin
1.9%
23.1%
Net Margin
0.7%
10.0%
Revenue YoY
42.9%
12.9%
Net Profit YoY
184.4%
4.0%
EPS (diluted)
$0.12

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ASTH
ASTH
PJT
PJT
Q4 25
$950.5M
$531.4M
Q3 25
$956.0M
$442.3M
Q2 25
$654.8M
$401.1M
Q1 25
$620.4M
$321.9M
Q4 24
$665.2M
$470.5M
Q3 24
$478.7M
$320.3M
Q2 24
$486.3M
$358.1M
Q1 24
$404.4M
$327.1M
Net Profit
ASTH
ASTH
PJT
PJT
Q4 25
$6.6M
$53.4M
Q3 25
$373.0K
$39.8M
Q2 25
$9.4M
$32.9M
Q1 25
$6.7M
$54.0M
Q4 24
$-7.8M
$51.3M
Q3 24
$16.1M
$22.1M
Q2 24
$19.2M
$28.3M
Q1 24
$14.8M
$32.6M
Operating Margin
ASTH
ASTH
PJT
PJT
Q4 25
1.9%
23.1%
Q3 25
2.0%
20.6%
Q2 25
3.1%
19.1%
Q1 25
3.3%
16.3%
Q4 24
0.1%
21.9%
Q3 24
5.9%
15.4%
Q2 24
6.2%
18.0%
Q1 24
7.5%
16.5%
Net Margin
ASTH
ASTH
PJT
PJT
Q4 25
0.7%
10.0%
Q3 25
0.0%
9.0%
Q2 25
1.4%
8.2%
Q1 25
1.1%
16.8%
Q4 24
-1.2%
10.9%
Q3 24
3.4%
6.9%
Q2 24
3.9%
7.9%
Q1 24
3.7%
10.0%
EPS (diluted)
ASTH
ASTH
PJT
PJT
Q4 25
$0.12
Q3 25
$0.01
Q2 25
$0.19
Q1 25
$0.14
Q4 24
$-0.14
Q3 24
$0.33
Q2 24
$0.40
Q1 24
$0.31

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ASTH
ASTH
PJT
PJT
Cash + ST InvestmentsLiquidity on hand
$429.5M
$538.9M
Total DebtLower is stronger
Stockholders' EquityBook value
$779.3M
$308.2M
Total Assets
$2.2B
$1.8B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ASTH
ASTH
PJT
PJT
Q4 25
$429.5M
$538.9M
Q3 25
$463.4M
$400.5M
Q2 25
$342.1M
$214.6M
Q1 25
$260.9M
$194.3M
Q4 24
$290.8M
$483.9M
Q3 24
$350.3M
$148.8M
Q2 24
$327.7M
$164.2M
Q1 24
$337.3M
$215.5M
Stockholders' Equity
ASTH
ASTH
PJT
PJT
Q4 25
$779.3M
$308.2M
Q3 25
$775.5M
$228.6M
Q2 25
$765.5M
$167.4M
Q1 25
$745.4M
$148.8M
Q4 24
$712.7M
$187.0M
Q3 24
$704.6M
$159.1M
Q2 24
$678.9M
$133.8M
Q1 24
$653.5M
$174.6M
Total Assets
ASTH
ASTH
PJT
PJT
Q4 25
$2.2B
$1.8B
Q3 25
$2.2B
$1.7B
Q2 25
$1.4B
$1.5B
Q1 25
$1.3B
$1.4B
Q4 24
$1.4B
$1.6B
Q3 24
$1.3B
$1.6B
Q2 24
$1.3B
$1.4B
Q1 24
$1.2B
$1.3B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ASTH
ASTH
PJT
PJT
Operating Cash FlowLast quarter
$-2.9M
$155.7M
Free Cash FlowOCF − Capex
$-6.0M
$138.6M
FCF MarginFCF / Revenue
-0.6%
26.1%
Capex IntensityCapex / Revenue
0.3%
3.2%
Cash ConversionOCF / Net Profit
-0.44×
2.92×
TTM Free Cash FlowTrailing 4 quarters
$104.5M
$480.4M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ASTH
ASTH
PJT
PJT
Q4 25
$-2.9M
$155.7M
Q3 25
$10.0M
$256.1M
Q2 25
$90.9M
$190.4M
Q1 25
$16.6M
$-75.9M
Q4 24
$-10.9M
$195.7M
Q3 24
$34.0M
$180.5M
Q2 24
$23.2M
$193.6M
Q1 24
$6.0M
$-38.8M
Free Cash Flow
ASTH
ASTH
PJT
PJT
Q4 25
$-6.0M
$138.6M
Q3 25
$7.4M
$240.9M
Q2 25
$89.5M
$178.9M
Q1 25
$13.6M
$-77.9M
Q4 24
$-13.5M
$195.3M
Q3 24
$31.7M
$178.5M
Q2 24
$20.4M
$193.0M
Q1 24
$5.6M
$-39.2M
FCF Margin
ASTH
ASTH
PJT
PJT
Q4 25
-0.6%
26.1%
Q3 25
0.8%
54.5%
Q2 25
13.7%
44.6%
Q1 25
2.2%
-24.2%
Q4 24
-2.0%
41.5%
Q3 24
6.6%
55.7%
Q2 24
4.2%
53.9%
Q1 24
1.4%
-12.0%
Capex Intensity
ASTH
ASTH
PJT
PJT
Q4 25
0.3%
3.2%
Q3 25
0.3%
3.4%
Q2 25
0.2%
2.9%
Q1 25
0.5%
0.6%
Q4 24
0.4%
0.1%
Q3 24
0.5%
0.6%
Q2 24
0.6%
0.1%
Q1 24
0.1%
0.1%
Cash Conversion
ASTH
ASTH
PJT
PJT
Q4 25
-0.44×
2.92×
Q3 25
26.69×
6.43×
Q2 25
9.65×
5.79×
Q1 25
2.48×
-1.41×
Q4 24
3.81×
Q3 24
2.11×
8.15×
Q2 24
1.21×
6.84×
Q1 24
0.40×
-1.19×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ASTH
ASTH

Medicare$542.4M57%
Commercial$99.1M10%
Care Delivery$92.1M10%
Care Enablement$78.9M8%
Other Third Parties$58.0M6%
Health Care Patient Service$39.8M4%
Health Care Other$25.5M3%
Other$12.1M1%
Management Service$10.3M1%

PJT
PJT

Segment breakdown not available.

Related Comparisons